Prelude

Cryoport Announces Multi-Year Agreement with Inception Fertility

Retrieved on: 
Tuesday, March 28, 2023
Inception, Prelude, Fertility, Partnership, Patient, Birth control

NASHVILLE, Tenn., March 28, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences industry and a leader in supply chain solutions for the reproductive medicine markets, today announced a multi-year agreement with Inception Fertility™ (Inception), North America's largest provider of comprehensive fertility services. Inception Fertility operates The Prelude Network® (Prelude), the largest and fastest-growing technology-led network of fertility centers in North America, and MyEggBank®, one of the largest and most diverse networks of donor egg banks and practices in North America.

Key Points: 
  • NASHVILLE, Tenn., March 28, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions for the life sciences industry and a leader in supply chain solutions for the reproductive medicine markets, today announced a multi-year agreement with Inception Fertility ™ (Inception), North America's largest provider of comprehensive fertility services.
  • Inception Fertility operates The Prelude Network ® (Prelude), the largest and fastest-growing technology-led network of fertility centers in North America, and MyEggBank ®, one of the largest and most diverse networks of donor egg banks and practices in North America.
  • "Making certain that patients' reproductive materials are safe at every touchpoint during the fertility transport journey is of the utmost importance as we serve a growing number of clients across the globe who trust us to handle these materials with care," added T.J. Farnsworth, CEO of Inception Fertility.
  • "Over the past three years, Cryoport has become an essential partner to the Inception team.

Prelude Therapeutics To Participate in Barclays Global Healthcare Conference

Retrieved on: 
Wednesday, March 1, 2023
Conference, Barclays, Pharmaceutical industry, Cryptocurrency, Prelude

WILMINGTON, Del., March 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Barclays Global Healthcare Conference in Miami, March 14 to 16, 2023.

Key Points: 
  • WILMINGTON, Del., March 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Barclays Global Healthcare Conference in Miami, March 14 to 16, 2023.
  • On March 16, at 9:30 a.m.
  • ET, Kris Vaddi, Ph.D., CEO of Prelude, and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat, hosted by Barclays.
  • The company will host one-on-one meetings on March 15 and 16.

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 14, 2022
BRM, Clinical trial, Brain, T-ALL, MYC, Thrombocytopenia, Monocyte, CLL, Safety, Security (finance), Anemia, Research and development, BTK, Prelude, R, Administration, Constipation, Drug resistance, CDK9, SMARCA4, Biotechnology, G&A, Research, Vomiting, NHL, COVID-19, Public expenditure, Incidence, Uveal melanoma, Large-cell lung carcinoma, FDA, Pharmacology, Sarcoma, BH3, CDK, Mesothelioma, Lymphoid neoplasms with plasmablastic differentiation, Hematological Cancer Research Investment and Education Act, Cancer, Pharmacokinetics, IND, MCL1, Fatigue, CD14, Glioma, Breast cancer, PRMT5, Human, SMARCA2, Risk, Nausea, Head, Patient, Pharmaceutical industry, Medical device

WILMINGTON, Del., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent clinical and development pipeline progress.

Key Points: 
  • I believe these programs offer the best chance to improve patient outcomes and I share our investigators excitement in our highly differentiated molecules.
  • Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents, and marketable securities as of September 30, 2022, were $224.0 million.
  • Prelude anticipates that its existing cash, cash equivalents and marketable securities will be sufficient to fund Preludes operations into the fourth quarter of 2024.
  • We expect our research and development expenses to vary from quarter to quarter, primarily due to the timing of our clinical development activities.

The Prelude Network® Expands its North America Footprint Through Partnership with Canada-Based Regional Fertility Program

Retrieved on: 
Tuesday, October 25, 2022
Fertility clinic, Physician, Pharmacy, Medicine, Cryopreservation, Science, LLC, Parent, PCRM, Reproductive medicine, Pacific Centre, Patient, IUI, ART, Research, Region, Bundled payment, Inception, History, Partnership, MacEwan University, RFP, Industry, CEO, Health, IVF, Fertility, Genetic testing, PGT, FRCSC, Fertility preservation, Leadership, Birth control, Medical device, Pharmacist, Prelude

HOUSTON, Oct. 25, 2022 /PRNewswire/ -- The Prelude Network® (Prelude), the largest and fastest-growing network of fertility clinics in North America, announces today its continued expansion through the partnership with Regional Fertility Program (RFP) in Alberta, Canada. This marks the second Canadian-based fertility clinic to join the Prelude family. In 2021, Prelude partnered with the Pacific Centre for Reproductive Medicine (PCRM), solidifying its place as the largest network of clinics in North America.

Key Points: 
  • Based in Alberta, Canada, RFP is the largest independent fertility clinic in Western Canada; marks the second Canadian-based provider to join North America's fastest growing network of clinics
    HOUSTON, Oct. 25, 2022 /PRNewswire/ -- The Prelude Network (Prelude), the largest and fastest-growing network of fertility clinics in North America, announces today its continued expansion through the partnership with Regional Fertility Program (RFP) in Alberta, Canada.
  • In 2021, Prelude partnered with the Pacific Centre for Reproductive Medicine (PCRM), solidifying its place as the largest network of clinics in North America.
  • "Prelude is proud to welcome Regional Fertility Program to our premium network of fertility clinics and extend our best-in-class practices to one of Canada's most prestigious fertility providers," says TJ Farnsworth, Founder and CEO of Inception Fertility , the parent company to Prelude.
  • The Prelude Network (Prelude), the fastest-growing network of fertility clinics and largest provider of comprehensive fertility services in North America, is the clinic network of Inception Fertility a family of fertility brands that touches every part of the fertility journey, including diagnostics and treatment to financial accessibility.

The Prelude Network® Announces 28 Abstracts Accepted, to be Presented at the 2022 ASRM Scientific Congress

Retrieved on: 
Monday, October 24, 2022
Fertility clinic, Physician, Medicine, Conference, Science, American Society for Reproductive Medicine, LLC, Reproductive medicine, Society, Patient, ART, Research, Bundled payment, Mental health, Inception, Episcopal conference, Knowledge, Goal, Industry, Health, NYU Langone Health, CEO, IVF, Fertility, 2021 Essex County Council election, Genetic testing, Infertility, PGT, Prelude, Fertility preservation, Leadership, Pharmaceutical industry, Medical device, Birth control, ASRM

HOUSTON, Oct. 24, 2022 /PRNewswire/ -- The Prelude Network® (Prelude), the largest and fastest-growing network of fertility clinics in North America, announces today that 28 of its abstracts have been accepted by the American Society for Reproductive Medicine (ASRM) and will be presented at the 2022 ASRM Scientific Congress, taking place October 22-26, 2022, in Anaheim, California.

Key Points: 
  • ASRM is a professional organization dedicated to advancing the science and practice of reproductive medicine.
  • Its annual Scientific Congress is a gathering of multi-disciplinary professionals who share the latest scientific breakthroughs and discoveries in reproductive endocrinology and infertility.
  • "We look forward to participating in ASRM, imparting our knowledge, and using this opportunity to learn from our colleagues."
  • To see a complete list of those Prelude abstracts that will be presented at the 2022 ASRM Scientific Congress, please visit Inception Fertility at ASRM 2022 Conference .

Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader

Retrieved on: 
Tuesday, October 18, 2022
U.S. Securities and Exchange Commission, Population, PRMT5, PRT, Family, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Biotechnology, BRG1, RNA, Security (finance), Cell, Technology, Private Securities Litigation Reform Act, Food, Goal, NSCLC, Cell death, Large-cell lung carcinoma, Pharmacokinetics, SMARCA2, Safety, CDK9, Survival, GLOBE, Brain, Forward-looking statement, DNA, BRM, FDA, COVID-19, MCL1, Prelude, Cancer, Risk, Pharmaceutical industry, Vaccine, IND, SMARCA4

Preclinical models with SMARCA4 deletions demonstrated that selective degradation of SMARCA2 with our potent and highly selective molecule PRT3789, resulted in significant anti-tumor activity at well tolerated doses, said Dr. Peggy Scherle, Chief Scientific Officer of Prelude.

Key Points: 
  • Preclinical models with SMARCA4 deletions demonstrated that selective degradation of SMARCA2 with our potent and highly selective molecule PRT3789, resulted in significant anti-tumor activity at well tolerated doses, said Dr. Peggy Scherle, Chief Scientific Officer of Prelude.
  • Historically, structural similarities between members of the SMARCA family have made it challenging to selectively inhibit SMARCA2.
  • Clearance of the IND for PRT3789 represents a major milestone for Prelude Therapeutics, as we advance our first-in-class SMARCA2 protein degrader from discovery to the clinic.
  • Preludes pipeline includes five candidates currently in clinical development: PRT811, a highly selective, potent, orally bioavailable PRMT5 inhibitor; PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645, a brain penetrant CDK4/6 inhibitor, and PRT3789, a SMARCA2/BRM protein degrader.

EVERI TO SHOWCASE NEWEST ADVANCEMENTS FOR ITS INDUSTRY-LEADING FINTECH AND REGTECH SOLUTIONS AT GLOBAL GAMING EXPO 2022

Retrieved on: 
Wednesday, October 5, 2022
Financial technology, Sale, Everi Holdings, IGaming Business, Growth, HTML, NYSE, G2E, UX, Apple Pay, PayPal, Hilltop Holdings Inc., Technology, Sport, CRT, Company, Imagination, Trilogy, Industry, HTML5, Banking as a service, CEO, Mobile backend as a service, Regulatory technology, Prelude, Solution, Casino, Online gambling, Cryptocurrency, Mobile phone

LAS VEGAS, Oct. 5, 2022 /PRNewswire/ -- Everi Holdings Inc. (NYSE: EVRI) ("Everi" or "the Company"), a premier provider of land-based and digital casino gaming content and products, financial technology, and player loyalty solutions, will showcase the newest enhancements for its "Digital Neighborhood", a fully-integrated suite of FinTech financial access, loyalty, and RegTech solutions, at the 22nd annual Global Gaming Expo (G2E®), October 10-13, 2022 (Booth #1150) in Las Vegas, Nevada. 

Key Points: 
  • "With the introduction of additional product advancements to our fully-integrated solutions, our FinTech business is even better positioned to deliver consistent growth and further build on our position as the industry's FinTech leader."
  • We believe our newest solutions on display at this year's G2E will once again highlight how Everi continues to successfully execute on our technology development priorities."
  • Everi's Trilogy loyalty platform represents a critical bridge between operator-centric financial technology solutions and player-centric gaming solutions.
  • With the support of a dedicated mobile app development team, Everi is a single-source provider of FinTech services across the entire gaming enterprise.

Calendly Acquires Prelude to Modernize the Recruitment Scheduling Experience

Retrieved on: 
Tuesday, September 27, 2022
Professional Services, Data Management, Business, Other Professional Services, Technology, Human Resources, Software, Touchpoint, Super Mario, CEO, Organization, Friction, Acquisition, Goal, Solution, Industry, Human, SMB, ATS, Applicant (sketch), Blog, Applicant tracking system, Risk management, Sales, Prelude

The addition of Prelude means that Calendly can accelerate its ambition to deliver deeper solutions for enterprise teams and organizations, serving as the one-stop shop for external scheduling.

Key Points: 
  • The addition of Prelude means that Calendly can accelerate its ambition to deliver deeper solutions for enterprise teams and organizations, serving as the one-stop shop for external scheduling.
  • With Prelude, Calendly will offer the leading scheduling automation platform for all segments of the industry, from SMBs to the enterprise.
  • Scheduling automation is really crucial to the success of any business team and together, Calendly and Prelude will be the clear choice.
  • Calendly will leverage Prelude for its enterprise customer base that are already using Calendlys single scheduling platform for multiple departments.

The Prelude Network® Launches Genetic Center of Excellence to Enhance Genetic Processes and Protocols

Retrieved on: 
Monday, August 29, 2022
Fertility preservation, Decision-making, Reproductive medicine, CEO, American Society for Reproductive Medicine, Bundled payment, Fertility clinic, Program, Research, Genetics, CGC, Genetic testing, PGT, Society, Parent, Topical steroid withdrawal, Genetic counseling, Science, Lists of diseases, IVF, Inception, Medicine, Fertility, Leadership, LLC, Black's, ART, Risk, MS, Growth, Industry, Patient, Agriculture, Medical device, Birth control, Prelude

HOUSTON , Aug. 29, 2022 /PRNewswire/ -- The Prelude Network® (Prelude), North America's largest and fastest-growing network of fertility clinics in North America, announces today the launch of its Genetic Center of Excellence, a new initiative that addresses the need for standardized genetic testing, genetic counseling and egg donor screening processes. The initial focus for the new program will be egg donor screening, which includes reviewing prospective donor family history and counseling about required genetic tests.

Key Points: 
  • HOUSTON, Aug. 29, 2022 /PRNewswire/ -- The Prelude Network (Prelude), North America's largest and fastest-growing network of fertility clinics in North America, announces today the launch of its Genetic Center of Excellence, a new initiative that addresses the need for standardized genetic testing, genetic counseling and egg donor screening processes.
  • This information is also vital to the donor, as it provides insight into any health concerns for their own future family planning.
  • "By launching the Genetic Center of Excellence program, aspiring parents can be assured that every effort is being made to help increase their chances of bringing home a baby."
  • The growing Prelude Network has over 40 total locations nationwide, offering a wide range of fertility services including egg freezing, IVF, genetic testing and egg/embryo storage, among others.

Inception Fertility Closes First Half of 2022 by Solidifying its Place as North America's Leader of Fertility Care

Retrieved on: 
Monday, August 15, 2022
CEO, Division, Ecosystem, Leadership, Research, Marketing, Patient, Egg, NYU Langone Health, Reproductive biology, REI, MD, Health, Industry, Technology, IVF, Prelude, PCRM, Reproductive medicine, Fertility, Partnership, Safety, Empathy, Doctor of Philosophy, PGT, Science, Physician, American Center for Reproductive Medicine, Living Archives on Eugenics in Western Canada, Mental health, Growth, Aspire, Fertility clinic, Acquisition, RMG, Parent, Bundled payment, Awareness, Fertility preservation, Organization, Woman, HFI, CRM, Associate, Inception, Center, ART, Medicine, Birth control, Infertility, Greater Houston

HOUSTON, Aug. 15, 2022 /PRNewswire/ -- The first half of 2022 for Inception Fertility™ solidified the organization's place as North America's premium fertility provider. The ecosystem of fertility brands, which includes a growing network of clinics (The Prelude Network®) and a fertility financial program (Bundl Fertility™), launched new service line offerings and important initiatives to draw heightened awareness around various aspects of the fertility industry, including physician recruitment efforts, and educational campaigns to help aspiring parents understand their fertility choices.

Key Points: 
  • Dr. Domar is also developing support systems for Inception's own team members to include mental health and wellness initiatives.
  • In addition to onboarding experts into the Inception family, the national leader in fertility care also embarked on a recruitment effort to encourage more physicians to enter the field of reproductive medicine.
  • In the last twelve months, Inception grew its network of fertility clinics, Prelude, by 45 percent to include more than 85 locations across North America.
  • Inception Fertility, (Inception) is a family of fertility brands committed to helping patients build their own families.